Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression.

TACI/TNFRSF13B biomarker breast cancer cancer metastasis platelets

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2021
Historique:
received: 15 12 2020
accepted: 01 03 2021
entrez: 5 4 2021
pubmed: 6 4 2021
medline: 6 4 2021
Statut: epublish

Résumé

Although treatment options in breast cancer have been improved significantly, predictive biomarkers for disease progression and metastasis are still lacking. Recent studies indicate that several TNF Receptor Superfamily members are involved in breast cancer cell proliferation and survival. Interestingly,

Identifiants

pubmed: 33816291
doi: 10.3389/fonc.2021.642170
pmc: PMC8010255
doi:

Types de publication

Journal Article

Langues

eng

Pagination

642170

Informations de copyright

Copyright © 2021 Hinterleitner, Zhou, Tandler, Heitmann, Kropp, Hinterleitner, Koch, Hartkopf, Zender, Salih and Maurer.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Ann Oncol. 2014 Oct;25(10):1901-1914
pubmed: 24769692
Cancers (Basel). 2019 Feb 26;11(3):
pubmed: 30813611
Nature. 1998 Feb 5;391(6667):591-4
pubmed: 9468137
Cancer Cell. 2015 Nov 9;28(5):666-676
pubmed: 26525104
Blood. 2008 Feb 1;111(3):1004-12
pubmed: 17942754
Neuro Oncol. 2017 Nov 29;19(12):1618-1627
pubmed: 28521029
Exp Hematol. 2004 Nov;32(11):1073-81
pubmed: 15539085
J Immunol. 2007 Dec 1;179(11):7276-86
pubmed: 18025170
Blood. 2015 Mar 12;125(11):1749-58
pubmed: 25631768
Science. 1997 Oct 3;278(5335):138-41
pubmed: 9311921
Anal Cell Pathol (Amst). 2011;34(1-2):49-60
pubmed: 21483105
Diabetes. 2018 Aug;67(8):1589-1603
pubmed: 29871859
Nat Rev Cancer. 2011 Feb;11(2):123-34
pubmed: 21258396
J Hematol Oncol. 2018 Oct 11;11(1):125
pubmed: 30305116
Front Immunol. 2020 Feb 05;11:44
pubmed: 32117229
Cancer Res. 2018 Jul 1;78(13):3407-3412
pubmed: 29921699
Cancer Immunol Immunother. 2021 Feb 4;:
pubmed: 33538861
BMC Genomics. 2016 Aug 12;17(1):631
pubmed: 27519173
J Leukoc Biol. 2001 Jan;69(1):123-8
pubmed: 11200056
J Innate Immun. 2011;3(4):374-82
pubmed: 21411974
Cytokine Growth Factor Rev. 2010 Feb;21(1):27-39
pubmed: 20004131
Carcinogenesis. 2015 May;36(5):574-84
pubmed: 25750171
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Front Oncol. 2018 Aug 07;8:301
pubmed: 30131941
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Pharmacol Ther. 2021 Jan;217:107630
pubmed: 32681846
Cancer Cell. 2011 Nov 15;20(5):576-90
pubmed: 22094253
Oncology. 2001;61 Suppl 2:67-72
pubmed: 11694790
Eur J Cancer. 2006 Apr;42(6):760-7
pubmed: 16510278
Oncogene. 2003 Mar 13;22(10):1517-27
pubmed: 12629515
Front Immunol. 2018 Oct 02;9:2125
pubmed: 30333819
Front Oncol. 2020 Jun 16;10:827
pubmed: 32612943
Blood. 2001 Aug 15;98(4):1047-54
pubmed: 11493450
Blood. 2004 Jan 15;103(2):679-88
pubmed: 14504101
Blood. 2017 Aug 3;130(5):567-580
pubmed: 28500171
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Clin Cancer Res. 2008 Nov 1;14(21):6735-41
pubmed: 18980965
J Immunol. 2015 Jan 15;194(2):542-52
pubmed: 25505277
Neurology. 2004 Feb 10;62(3):498-501
pubmed: 14872043
Cytokine. 2020 Jan;125:154790
pubmed: 31400636
Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14266-71
pubmed: 26578771
Mol Syst Biol. 2017 Nov 3;13(11):951
pubmed: 29101300
J Immunol. 2012 Jul 1;189(1):154-60
pubmed: 22649191
Front Immunol. 2018 May 04;9:847
pubmed: 29780381
Cancer Res. 1999 Mar 15;59(6):1295-300
pubmed: 10096562
J Immunol. 2009 Nov 1;183(9):5948-56
pubmed: 19828625
Cancer Res. 2012 Jan 15;72(2):440-8
pubmed: 22127925
BMC Cancer. 2008 Mar 20;8:76
pubmed: 18366696
Blood. 2005 Aug 1;106(3):1021-30
pubmed: 15827134
Nat Rev Immunol. 2009 Jul;9(7):491-502
pubmed: 19521398
Cell Death Differ. 2008 Feb;15(2):251-62
pubmed: 17975553

Auteurs

Clemens Hinterleitner (C)

Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany.
Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, Germany.

Yanjun Zhou (Y)

Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, Germany.
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.

Claudia Tandler (C)

Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, Germany.
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.

Jonas S Heitmann (JS)

Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, Germany.
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.

Korbinian N Kropp (KN)

Department of Hematology, Medical Oncology and Pneumology, University Medical Center of Mainz, Mainz, Germany.

Martina Hinterleitner (M)

Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany.
Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, Germany.

André Koch (A)

Department of Obstetrics and Gynecology, University Hospital Tuebingen, Tuebingen, Germany.

Andreas D Hartkopf (AD)

Department of Obstetrics and Gynecology, University Hospital Tuebingen, Tuebingen, Germany.

Lars Zender (L)

Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany.
Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, Germany.
German Cancer Research Consortium (DKTK), Partner Site Tübingen, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Helmut R Salih (HR)

Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, Germany.
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.

Stefanie Maurer (S)

Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, Germany.
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Classifications MeSH